Milestones, expansions, and partnerships from across our network. For media inquiries, reach us at press@diabryx.com.
Our Aldercrest, Oregon campus has commissioned a new commercial-scale LNP drug product suite, adding aseptic fill-finish capacity to support partners advancing programs toward market launch.
Diabryx has completed validation runs demonstrating that FluxMix™ encapsulation holds particle size and encapsulation efficiency constant from gram to multi-gram scale, removing a key scale-up risk for partners.
A leading infectious-disease vaccine developer has reserved dedicated drug substance and drug product capacity at Diabryx to secure supply across its clinical and early commercial pipeline.
Diabryx has launched end-to-end self-amplifying mRNA services — from construct support through purification and LNP delivery — extending our platform to lower-dose, longer-expression modalities.
Quality leader Daniel Moreau joins Diabryx to lead its quality systems and regulatory strategy, bringing a track record of clean inspections across multiple jurisdictions.
Our Lindqvist, Sweden site has expanded its analytical development center with new instrumentation for circular RNA characterization and high-throughput LNP particle analysis.
Want program-relevant updates from Diabryx? Drop us a line and we'll keep you posted on capacity, capabilities, and milestones.